Extracellular vesicles (EVs) are tiny particles released by our cells, carrying proteins, lipids, and genetic material. In heart and vascular diseases, these messengers play an active role in inflammation, clot formation, vessel damage, and even heart muscle remodeling.
Different types of EVs provide valuable clues about health:
Platelet-derived EVs can indicate clotting risk and acute cardiac events.
Endothelial EVs reflect vessel injury and dysfunction.
Leukocyte/monocyte EVs show immune activation.
EVs rich in microRNAs like miR-21, miR-126, and miR-146a have been linked to heart attacks, heart failure, and hypertension.
Because of these signals, EVs are being studied as biomarkers for early detection, disease monitoring, and predicting outcomes. On the therapeutic side, engineered EVs and stem cell–derived EVs are being explored to deliver protective molecules, repair tissues, and support recovery after heart injury.
The road ahead isn’t without challenges—standardizing EV detection, understanding their diversity, and proving their reliability in large populations are key steps. But the potential is huge for truly personalized and precise cardiac care.
Early detection of diseases require capital investment. If a new test could detect such problems years before symptoms, would you go for it? Would you get check-up for a disease you don’t have yet?
Extracellular vesicles (EVs) are tiny cellular messengers that reveal heart and vessel health.
They can serve as biomarkers for early detection of heart attacks, heart failure, and clotting risk.
Yes, early detection of the disease will save us from huge cost that we will face in the future if we get that disease as the saying prevention is better than cure
Yes, I would go for early detection of diseases if a new test is available. Many of the illnesses, including cancers, are easily curable if detected earlier. Also, people are very health-conscious these days and are doing routine medical check-ups.
Yes, I would go for it if it is accurate, affordable, and leads to effective treatment. Early detection could make me aware of my health condition and potentially save my life.
EVs are tiny nano sized particles released by various cells of the body. They reflect the physiological health of parent cell. Therefore they can be used as early detection molecular biomarkers as they reflect the health of the cells they are secreted from. There is a need for standardization of the techniques if EVs are being utilised as diagnostics.This can be a next generation advancement in the medical field as doctors may also use these markers as indicators of cardiac stress and not only relying on conventional options like ECG.
This looks promising for early detection, but the true test will be overcoming the cost and standardization barriers to make this precision treatment available to everybody, not just the rich.
Serious heart conditions may be avoided before symptoms manifest by using sophisticated tests for early detection, such as EV analysis. Although the concept of proactive health monitoring is attractive, accessibility, cost, and test accuracy are important considerations. If getting checked would result in better outcomes and peace of mind, many people would consider doing so; however, widespread adoption requires convincing evidence and reasonably priced options.
In heart and vascular diseases, these messengers play an active role in inflammation, clot formation, vessel damage, and even heart muscle remodeling. 
But the potential is huge for truly personalized and precise cardiac care. 
Early detection of diseases require capital investment. If a new test could detect such problems years before symptoms, would you go for it? Would you get check-up for a disease you don’t have yet?